Raxtozinameran

DB18228ApprovedInvestigationalVaccines

Raxtozinameran is a Pfizer mRNA vaccine used to prevent COVID-19 caused by SARS-CoV-2. Raxtozinameran is also known as Pfizer-BioNTech COVID-19 Vaccine and Comirnaty.

Mechanism
Curator reviewed · 5 references
Primary indication
Raxtozinameran is indicated for the active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.Curator reviewed · 1 structured indication
First approval
Canada, 2023 · United States, 2023
Also known as
BNT162b2 Omicron (XBB.1.5) · messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike (S) glycoprotein (Omicron sub-lineage XBB.1.5; · Pfizer-BioNTech COVID-19 Vaccine 2023-2024 · RBP-020.2 4 (XBB.1.5 variant) · RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptide plus codon-optimized pre-fusion spik

Resolves to

Clinical / RWD
Targets

What you can answer from here — as of October 16, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
290Drug interactionsStructured to mechanism, not free text
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
13Marketed productsAcross 3 countries and 5 labellers
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Raxtozinameran, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account